Cargando…

Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens

Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose‐limiting toxicity (DLT) in colon can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Raafi, Baracos, Vickie E., Sawyer, Michael B., Bianchi, Laurent, Roberts, Sarah, Assenat, Eric, Mollevi, Caroline, Senesse, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831278/ https://www.ncbi.nlm.nih.gov/pubmed/26814378 http://dx.doi.org/10.1002/cam4.621

Ejemplares similares

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis
por: Tezuka, Shun, et al.
Publicado: (2021)

The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients
por: Zhou, Juan, et al.
Publicado: (2016)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer
por: Degirmencioglu, Serkan, et al.
Publicado: (2019)

The Role of Intestinal Microbiota in Development of Irinotecan Toxicity and in Toxicity Reduction through Dietary Fibres in Rats
por: Lin, Xiaoxi B., et al.
Publicado: (2014)

Prevotella contributes to individual response of FOLFOX in colon cancer
por: Hou, Xiao‐Ying, et al.
Publicado: (2021)

Bilateral optic disc oedema and associated optic neuropathy in the setting of FOLFOX chemotherapy
por: Turner, Liam D, et al.
Publicado: (2013)

The effect of breast volume on toxicity using hypofractionated regimens for early stage breast cancer for patients
por: Butler-Xu, Yiqing Shirley, et al.
Publicado: (2018)

FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms
por: Lu, Wei, et al.
Publicado: (2020)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
por: Hou, Xiaoying, et al.
Publicado: (2021)

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Anterior ischemic optic neuropathy in a patient with optic disc Drusen while on FOLFOX Chemotherapy for colon cancer: the value of Occam’s Razor and Hickam’s dictum
por: Elnahry, Gehad Ayman
Publicado: (2019)

Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
por: Salehifar, Ebrahim, et al.
Publicado: (2019)

Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study
por: Jongeneel, Gabrielle, et al.
Publicado: (2021)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Rapid Standardized CT-Based Method to Determine Lean Body Mass SUV for PET—A Significant Improvement Over Prediction Equations
por: Riauka, Terence A., et al.
Publicado: (2022)

Pitfalls in defining and quantifying cachexia
por: Baracos, Vickie E.
Publicado: (2011)

Psoas as a sentinel muscle for sarcopenia: a flawed premise
por: Baracos, Vickie E.
Publicado: (2017)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
por: Liu, Mengyao, et al.
Publicado: (2018)

Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: Case report
por: Fukuda, Masafumi, et al.
Publicado: (2020)

Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China
por: Zhang, Dan, et al.
Publicado: (2019)

Chemotherapeutic Risk lncRNA-PVT1 SNP Sensitizes Metastatic Colorectal Cancer to FOLFOX Regimen
por: Wu, Shenshen, et al.
Publicado: (2022)

The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients
por: Hsieh, Mei‐Chin, et al.
Publicado: (2016)

Subcutaneous adiposity is an independent predictor of mortality in cancer patients
por: Ebadi, Maryam, et al.
Publicado: (2017)

Colon cancer checks in when bile acids check out: the bile acid–nuclear receptor axis in colon cancer
por: Tang, Qin, et al.
Publicado: (2021)

Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy
por: Chu, Michael P., et al.
Publicado: (2015)

Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy
por: Chu, Michael P., et al.
Publicado: (2016)

Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
por: Tsai, Yi-Jian, et al.
Publicado: (2016)

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
por: Murray, Nigel P, et al.
Publicado: (2019)

Commentary: Intermittent Fasting and Akkermansia Muciniphila Potentiate the Antitumor Efficacy of FOLFOX in Colon Cancer
por: Su, Junhong, et al.
Publicado: (2022)

The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
por: Chen, Minxue, et al.
Publicado: (2020)

Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
por: Sugihara, Kenichi, et al.
Publicado: (2012)

LINC01123 facilitates proliferation, invasion and chemoresistance of colon cancer cells
por: Ye, Shicai, et al.
Publicado: (2020)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ghcm8p197ampolqpou4vrakhro